JP2023162343A5 - - Google Patents

Download PDF

Info

Publication number
JP2023162343A5
JP2023162343A5 JP2023139455A JP2023139455A JP2023162343A5 JP 2023162343 A5 JP2023162343 A5 JP 2023162343A5 JP 2023139455 A JP2023139455 A JP 2023139455A JP 2023139455 A JP2023139455 A JP 2023139455A JP 2023162343 A5 JP2023162343 A5 JP 2023162343A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
antibody
antigen
binding fragment
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023139455A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023162343A (ja
JP7636487B2 (ja
Filing date
Publication date
Priority claimed from JP2020036331A external-priority patent/JP6893265B2/ja
Application filed filed Critical
Publication of JP2023162343A publication Critical patent/JP2023162343A/ja
Publication of JP2023162343A5 publication Critical patent/JP2023162343A5/ja
Priority to JP2025020415A priority Critical patent/JP7842268B2/ja
Application granted granted Critical
Publication of JP7636487B2 publication Critical patent/JP7636487B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023139455A 2014-02-21 2023-08-30 Il-4r拮抗薬の投与により喘息を処置または予防するための方法 Active JP7636487B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025020415A JP7842268B2 (ja) 2014-02-21 2025-02-12 Il-4r拮抗薬の投与により喘息を処置または予防するための方法

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201461943019P 2014-02-21 2014-02-21
US61/943,019 2014-02-21
EP14306413 2014-09-15
EP14306413.7 2014-09-15
US201462077669P 2014-11-10 2014-11-10
US62/077,669 2014-11-10
JP2020036331A JP6893265B2 (ja) 2014-02-21 2020-03-04 Il−4r拮抗薬の投与により喘息を処置または予防するための方法
JP2021089717A JP7343547B2 (ja) 2014-02-21 2021-05-28 Il-4r拮抗薬の投与により喘息を処置または予防するための方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021089717A Division JP7343547B2 (ja) 2014-02-21 2021-05-28 Il-4r拮抗薬の投与により喘息を処置または予防するための方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025020415A Division JP7842268B2 (ja) 2014-02-21 2025-02-12 Il-4r拮抗薬の投与により喘息を処置または予防するための方法

Publications (3)

Publication Number Publication Date
JP2023162343A JP2023162343A (ja) 2023-11-08
JP2023162343A5 true JP2023162343A5 (https=) 2024-07-25
JP7636487B2 JP7636487B2 (ja) 2025-02-26

Family

ID=51570453

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016552595A Active JP6673840B2 (ja) 2014-02-21 2015-02-20 Il−4r拮抗薬の投与により喘息を処置または予防するための方法
JP2023139455A Active JP7636487B2 (ja) 2014-02-21 2023-08-30 Il-4r拮抗薬の投与により喘息を処置または予防するための方法
JP2025020415A Active JP7842268B2 (ja) 2014-02-21 2025-02-12 Il-4r拮抗薬の投与により喘息を処置または予防するための方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016552595A Active JP6673840B2 (ja) 2014-02-21 2015-02-20 Il−4r拮抗薬の投与により喘息を処置または予防するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025020415A Active JP7842268B2 (ja) 2014-02-21 2025-02-12 Il-4r拮抗薬の投与により喘息を処置または予防するための方法

Country Status (15)

Country Link
US (3) US10137193B2 (https=)
EP (3) EP3107575B1 (https=)
JP (3) JP6673840B2 (https=)
KR (4) KR102368450B1 (https=)
CN (1) CN106232140A (https=)
AU (3) AU2015218808B2 (https=)
CA (2) CA3249780A1 (https=)
ES (2) ES2897631T3 (https=)
HU (1) HUE065844T2 (https=)
IL (1) IL315136A (https=)
MX (2) MX384192B (https=)
PL (2) PL3973987T3 (https=)
PT (2) PT3973987T (https=)
RU (1) RU2713406C2 (https=)
WO (1) WO2015127229A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
JP6306588B2 (ja) * 2012-08-21 2018-04-04 サノフィ・バイオテクノロジー Il−4rアンタゴニストを投与することにより喘息を処置又は予防するための方法
PL2892927T3 (pl) 2012-09-07 2018-11-30 Regeneron Pharmaceuticals, Inc. Sposoby leczenia atopowego zapalenia skóry przez podawanie antagonisty IL-4R
TWI755763B (zh) * 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
AU2014284235C1 (en) * 2013-06-21 2025-07-31 Regeneron Pharmaceuticals, Inc. Methods for treating nasal polyposis by administering an IL-4R antagonist
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法
EP3838271B1 (en) 2013-07-12 2025-09-03 Areteia Therapeutics, Inc. Treating elevated levels of eosinophils and/or basophils
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
KR102695088B1 (ko) 2014-02-28 2024-08-16 리제너론 파아마슈티컬스, 인크. Il-4r 길항제의 투여에 의한 피부 감염의 치료 방법
CA3246946A1 (en) 2014-11-14 2025-11-29 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
US20180056018A1 (en) * 2016-08-31 2018-03-01 Cephalon, Inc. Inhalation Systems, Devices and Methods
ES2994774T3 (en) 2016-09-01 2025-01-31 Regeneron Pharma Methods for preventing or treating allergy by administering an il-4r antagonist
WO2018057776A1 (en) 2016-09-22 2018-03-29 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
RU2759630C2 (ru) 2016-09-22 2021-11-16 Ридженерон Фармасьютикалз, Инк. Способы лечения тяжелого атопического дерматита путем введения ингибитора il-4r
TWI857389B (zh) * 2016-12-01 2024-10-01 美商再生元醫藥公司 治療發炎症狀的方法
ES3052989T3 (en) * 2017-04-13 2026-01-16 Regeneron Pharma Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1
US11850283B2 (en) 2017-06-27 2023-12-26 Ohio State Innovation Foundation Liponucleotide-based therapy for asthma
EP3645009A4 (en) 2017-06-27 2021-03-31 The Ohio State Innovation Foundation LIPONUCLEOTIDE THERAPY FOR COPD
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
KR102694419B1 (ko) * 2017-10-30 2024-08-09 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
BR112020020387A2 (pt) 2018-05-13 2021-01-19 Regeneron Pharmaceuticals, Inc. Métodos para o tratamento de dermatite atópica por administração de um inibidor de il-4r
AU2019302642B2 (en) 2018-07-10 2025-10-30 Regeneron Pharmaceuticals, Inc. Modifying binding molecules to minimize pre-existing interactions
CN110872349A (zh) * 2018-09-04 2020-03-10 三生国健药业(上海)股份有限公司 结合人il-4r的抗体、其制备方法和用途
CN110746507B (zh) 2018-12-25 2020-06-26 江苏荃信生物医药有限公司 抗人白介素4受体α单克隆抗体及其应用
CN116813770A (zh) * 2018-12-27 2023-09-29 中山康方生物医药有限公司 抗人il-4ra的抗体及其用途
CN113597328B (zh) 2019-03-21 2025-10-31 瑞泽恩制药公司 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合
SG11202111255YA (en) * 2019-05-01 2021-11-29 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-33 antagonist
WO2021011614A1 (en) * 2019-07-16 2021-01-21 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
JP7836754B2 (ja) 2019-08-05 2026-03-27 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Il-4rアンタゴニストを投与することによりアレルギーを治療しアレルゲン特異的免疫療法を増強するための方法
CN114173816A (zh) 2019-08-05 2022-03-11 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗特应性皮炎的方法
EP3992974A1 (en) 2020-11-02 2022-05-04 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
KR20220110829A (ko) 2019-12-09 2022-08-09 사노피 바이오테크놀로지 디지털 식별된 il-4/il-13 관련 장애의 치료 방법
CN113797331A (zh) * 2020-06-16 2021-12-17 三生国健药业(上海)股份有限公司 一种稳定的抗IL-4Rα单克隆抗体液体制剂
EP4192453A4 (en) * 2020-08-05 2024-11-13 Areteia Therapeutics, Inc. USE OF DEXPRAMIPEXOLE TO TREAT MODERATE TO SEVERE ASTHMA
US20220169739A1 (en) * 2020-10-05 2022-06-02 Sanofi Biotechnology Methods for treating asthma in pediatric subjects by administering an il-4r antagonist
KR20240053586A (ko) * 2021-08-26 2024-04-24 치아타이 티안큉 파마수티컬 그룹 주식회사 항il4r 항체의 의약 조성물 및 그의 사용
CN117368487A (zh) * 2023-09-28 2024-01-09 首都医科大学附属北京同仁医院 一种利用局部IgE预测或评估奥马珠单抗在治疗复发性鼻息肉中疗效的方法和应用
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8808015D0 (en) 1988-04-06 1988-05-05 Ritter M A Chemical compounds
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5714146A (en) 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
EP0604693A1 (en) 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
EP2990420B1 (en) 2000-05-26 2016-12-21 Immunex Corporation Use of interleukin-4 receptor antibodies and compositions thereof
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
MXPA06004853A (es) 2003-11-07 2006-07-06 Immunex Corp Anticuerpos que se aglutinan al receptor 4 de interleucina.
CA2550933A1 (en) 2003-12-22 2005-07-14 Amgen Inc. Methods for identifying functional antibodies
AU2005219837A1 (en) 2004-02-27 2005-09-15 Regeneron Pharmaceuticals, Inc. IL-4/IL-13 sepecific polypetides and therapeutic uses thereof
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
TW200902555A (en) 2005-01-03 2009-01-16 Hoffmann La Roche Antibodies against IL-13 receptor alpha 1 and uses thereof
JP2009523460A (ja) * 2006-01-24 2009-06-25 ドマンティス リミテッド Il−4および/またはil−13に結合するリガンド
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
CN101522716B (zh) 2006-10-02 2013-03-20 瑞泽恩制药公司 抗人il-4受体的高亲和力人抗体
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
EP2022507A1 (en) 2007-08-07 2009-02-11 Universität Hamburg Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
BRPI0822099A2 (pt) * 2007-12-21 2017-05-23 Medimmune Ltd membro de ligação isolado, uso de um membro de ligação isolado, método parav tratar um distúrbio, molécula de ácido nucléico isolada, célula hospedeira, e, método para produzir um membro de ligação
EP2376656A4 (en) 2008-12-01 2012-05-16 Cincinnati Children S Hospital Medical Ct METHOD AND DETERMINATION OF THE EFFECTIVENESS OF A GLUCOCORTICOID TREATMENT OF EOSINOPHILIAN ESOPHAGITIS
WO2010120524A2 (en) 2009-03-31 2010-10-21 Altair Therapeutics, Inc. Methods of modulating an immune response to a viral infection
WO2011156000A2 (en) * 2010-06-07 2011-12-15 Aerovance, Inc. Use of il-4/il-13 antagonists to treat eosinophilic disorders
BR112013008366B1 (pt) 2010-10-06 2022-02-08 Regeneron Pharmaceuticals, Inc Formulações farmacêuticas líquidas estáveis contendo anticorpos anti-receptor de interleucina-4 humana alfa, e recipiente contendo as referidas formulações
MX2013004212A (es) * 2010-10-15 2013-09-02 Medimmune Ltd Terapias para mejorar la funcion pulmonar.
US20130052190A1 (en) 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
HK1201440A1 (en) * 2011-11-01 2015-09-04 Medimmune, Llc Methods for reducing the frequency and severity of acute exacerbations of asthma
JP6306588B2 (ja) 2012-08-21 2018-04-04 サノフィ・バイオテクノロジー Il−4rアンタゴニストを投与することにより喘息を処置又は予防するための方法
PL2892927T3 (pl) 2012-09-07 2018-11-30 Regeneron Pharmaceuticals, Inc. Sposoby leczenia atopowego zapalenia skóry przez podawanie antagonisty IL-4R
AU2014284235C1 (en) 2013-06-21 2025-07-31 Regeneron Pharmaceuticals, Inc. Methods for treating nasal polyposis by administering an IL-4R antagonist
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
CA3246946A1 (en) 2014-11-14 2025-11-29 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
KR102694419B1 (ko) * 2017-10-30 2024-08-09 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
US20220169739A1 (en) 2020-10-05 2022-06-02 Sanofi Biotechnology Methods for treating asthma in pediatric subjects by administering an il-4r antagonist

Similar Documents

Publication Publication Date Title
JP2023162343A5 (https=)
JP2025072593A5 (https=)
JP2017507139A5 (https=)
JP2023139071A5 (https=)
JP2023103389A (ja) Il-4r阻害剤の投与によるアレルギー処置方法およびアレルゲン特異的免疫療法の向上方法
RU2016136364A (ru) Способы лечения или предупреждения астмы посредством введения антагониста il-4r
US6623736B2 (en) Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
JP2022160685A5 (https=)
CN104755495A (zh) 通过施用il-4r拮抗剂治疗或预防哮喘的方法
CA2918105C (en) Methods for reducing exacerbation rates of asthma using benralizumab
RU2015114923A (ru) СПОСОБЫ ЛЕЧЕНИЯ IL-1β-ЗАВИСИМЫХ ЗАБОЛЕВАНИЙ
JP2009541374A5 (https=)
CN102947336A (zh) 用dll4拮抗剂治疗糖尿病的方法
RU2014101207A (ru) Новые показания к применению при лечении антителами против il-1-бета
KR102337599B1 (ko) 벤랄리주맙을 이용하여 천식 환자에서 강제 호기량을 증가시키는 방법
RU2014117510A (ru) Лечение ревматоидного артрита
JPWO2021026205A5 (https=)
JP2021523881A5 (https=)
CN118355034A (zh) 施用il-4/il-13拮抗剂以减弱特应性进程的方法
JP2020073525A5 (https=)
JPWO2020223541A5 (https=)
JP2019535716A5 (https=)
JP2005529152A5 (https=)
CA3176673A1 (en) Pan-elr+ cxc chemokine antibodies for the treatment of respiratory disease
JPWO2021113707A5 (https=)